Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Shock Waves01:16

Shock Waves

2.6K
While deriving the Doppler formula for the observed frequency of a sound wave, it is assumed that the speed of sound in the medium is greater than the source's speed through it. When this condition is breached, a shock wave occurs.
When the source's speed approaches the speed of sound, constructive interference between successive wavefronts emitted by the source occurs immediately behind it. Initially, scientists believed that this constructive interference would result in such high...
2.6K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

601
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
601
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

2.9K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.9K
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.7K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.7K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.7K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

797
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
797

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of pneumatic tube systems on next-generation viscoelastic coagulation test devices in septic patients and healthy individuals: Results of the randomized controlled VETaPT trial.

Scientific reports·2026
Same author

Viscoelastic point-of-care testing for monitoring unfractionated heparin in critically ill patients: a prospective observational study comparing ClotPro® IN/HI-Test, aPTT and Anti-Xa activity.

BMC anesthesiology·2026
Same author

[Regional anesthesia under anticoagulation : Comparison of guidelines and recommendations for action].

Schmerz (Berlin, Germany)·2026
Same author

[Ventilation strategies in intensive care medicine].

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS·2026
Same author

Effects of the primary lung infection on outcomes in patients with severe ARDS treated with ECMO: a retrospective analysis.

Frontiers in medicine·2025
Same author

Clinical Phenotyping in Acute Respiratory Distress Syndrome: Steps Towards Personalized Medicine.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Feb 2, 2026

Characterizing Salmonella Typhimurium-induced Septic Peritonitis in Mice
14:10

Characterizing Salmonella Typhimurium-induced Septic Peritonitis in Mice

Published on: July 29, 2022

5.9K

[Beta-blockers in Septic Shock].

Christopher Uhlig, Peter Markus Spieth

    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
    |November 21, 2018
    PubMed
    Summary

    Beta-blockers may help manage persistent tachycardia in septic shock, but careful use is crucial. Incautious administration can worsen hypotension and shock due to negative inotropic effects.

    Area of Science:

    • Critical Care Medicine
    • Pharmacology
    • Cardiovascular Physiology

    Background:

    • Sepsis and septic shock present significant challenges in critical care.
    • Initial septic shock often involves hyperdynamic circulation, tachycardia, and hemodynamic instability.
    • Persistent sinus tachycardia may indicate adrenergic overstimulation, even with adequate fluid therapy.

    Purpose of the Study:

    • To review the pharmacology of the beta-adrenergic system.
    • To explore the pathophysiological rationale for beta-blocker use in sepsis.
    • To examine current literature on clinical applications of beta-blockers in sepsis and septic shock.

    Main Methods:

    • Literature review of beta-adrenergic system pharmacology.
    • Analysis of pathophysiological mechanisms in sepsis.

    More Related Videos

    Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
    08:27

    Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

    Published on: May 21, 2018

    11.4K
    Drosophila Adult Olfactory Shock Learning
    09:48

    Drosophila Adult Olfactory Shock Learning

    Published on: August 7, 2014

    29.2K

    Related Experiment Videos

    Last Updated: Feb 2, 2026

    Characterizing Salmonella Typhimurium-induced Septic Peritonitis in Mice
    14:10

    Characterizing Salmonella Typhimurium-induced Septic Peritonitis in Mice

    Published on: July 29, 2022

    5.9K
    Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
    08:27

    Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

    Published on: May 21, 2018

    11.4K
    Drosophila Adult Olfactory Shock Learning
    09:48

    Drosophila Adult Olfactory Shock Learning

    Published on: August 7, 2014

    29.2K
  • Synthesis of clinical practice guidelines and research on beta-blocker therapy.

    • Main Results:

    • Beta-adrenergic system plays a role in sepsis pathophysiology.
    • Selective beta-1 blockers may offer benefits in specific septic shock cases.
    • Beta-blocker administration requires caution due to potential negative inotropic effects and risk of worsening shock.

    Conclusions:

    • Beta-blockers represent a potential therapeutic option for managing specific aspects of septic shock.
    • Careful patient selection and monitoring are essential to mitigate risks associated with beta-blocker use.
    • Further research is needed to optimize the role of beta-blockers in sepsis management.